Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.66 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.56 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.56 |
| ▸ | CNR2 | P34972 | 10/20 | 0.55 |
| ▸ | CNR1 | P21554 | 7/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9238742 | 0.84 | SMN1; SMN2 (0.55) | SMN1; SMN2CREBBPALDH1A1KMT2ANR2F2 | |
| SCHEMBL5332746 | 0.84 | SMN1; SMN2 (0.71) | SMN1; SMN2CREBBPALDH1A1KMT2ANR2F2 | |
| SCHEMBL17176279 | 0.82 | CREBBP (0.73) | SMN1; SMN2CREBBPALDH1A1KMT2ANR2F2 | |
| SCHEMBL16129420 | 0.82 | CNR2 (0.80) | CNR2CNR1 | |
| SCHEMBL6587056 | 0.82 | NR4A2 (0.70) | SMN1; SMN2ALDH1A1KMT2ACNR2CNR1 | |
| SCHEMBL28725466 | 0.81 | SMN1; SMN2 (0.63) | SMN1; SMN2CREBBPALDH1A1KMT2ANR2F2 | |
| SCHEMBL2554994 | 0.79 | CREBBP (1.00) | SMN1; SMN2CREBBPALDH1A1KMT2ANR2F2 | |
| SCHEMBL7381548 | 0.79 | CNR2 (0.60) | CNR2CNR1 | |
| SCHEMBL13166897 | 0.79 | NR4A2 (0.54) | SMN1; SMN2ALDH1A1KMT2ACNR2CNR1 | |
| SCHEMBL5450086 | 0.79 | CNR2 (0.62) | SMN1; SMN2CREBBPALDH1A1KMT2ANR2F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230120881-A1 | BINUCLEAR GOLD(I) COMPOUNDS FOR PHOTOCATALYSIS APPLICATIONS | University of Hong Kong Versitech Limited (CN) | 2023-04-20 | — | — | US | disclosed |
| EP-4122940-A1 | BINUCLEAR GOLD(I) COMPOUNDS FOR PHOTOCATALYSIS APPLICATIONS | Versitech Limited (CN) | 2023-01-25 | — | — | EP | disclosed |
| CN-115636840-A | Binuclear gold (I) compounds for photocatalytic applications | 港大科桥有限公司 | 2023-01-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230120881-A1 | BINUCLEAR GOLD(I) COMPOUNDS FOR PHOTOCATALYSIS APPLICATIONS | PPOX, AP3M1, AP2M1 | SMN1; SMN2 4866/4885CREBBP 4459/4885ALDH1A1 657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.